Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Only Released Limited Phase 1 Data for Its Novel Coronavirus Vaccine

By Brian Orelli, PhD – Jun 4, 2020 at 3:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The decision came as the result of a natural disagreement between the scientists and the investors.

At drug companies, when new clinical trial data becomes available, there's typically a tug-of-war between the scientists and the investors. The people doing the research and development want to hold onto their data until it's properly ready for publication because most of the premier journals won't publish data that's been previously reported. Investors, on the other hand, want to see the data as soon as possible because it affects the prospects for the company.

The compromise is usually that some top-line data gets released early, but not nearly enough to satisfy investors. Such was the case for Moderna (MRNA 2.12%) when it released data for just eight of the 45 participants in the phase 1 clinical trial testing its SARS-CoV-2 vaccine, mRNA-1273.

"The NIH is running the study, and they want to be able to publish the data," CEO Stephane Bancel explained Wednesday at the Jefferies 2020 Healthcare Conference, which was held virtually.

Nevertheless, Bancel and Moderna's board of directors felt the data on the first eight patients had to be released, "We were worried that with so many people aware of the data that it was not possible for the company to fulfill our obligation to ensure that we have no material information leaving the company."

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Bancel noted that the data might be released by the NIH in a non-peer-reviewed format before being formally published, although that's outside of Moderna's control.

The company has already started a 600-patient phase 2 clinical trial for the vaccine and expects its phase 3 study to start in July.

Bancel said it's possible that Moderna could get an Emergency Use Authorization (EUA) from the Food and Drug Administration based on the phase 2 data. The EUA would likely only cover people whose need for protection from COVID-19 is the most pressing -- healthcare workers and perhaps some other categories of essential workers -- although Bancel noted that supplies of mRNA-1273 will likely be constrained at that point, so the company couldn't offer vaccinations to everyone even if the FDA signed off on a broader authorization.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.23 (2.12%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.